Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Prof. Lior Rosenberg M.D. |
IPO Date | March 20, 2014 |
Location | Israel |
Headquarters | 42 Hayarkon Street, Yavne, Israel, 8122745 |
Employees | 100 |
Sector | Healthcare |
Industry | Biotechnology |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
NA
NA
NA
NA
NA
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email